- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting TRAIL in the treatment of cancer: new developments
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 19, Issue 9, Pages 1171-1185
Publisher
Informa Healthcare
Online
2015-05-25
DOI
10.1517/14728222.2015.1049838
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).
- (2017) D. Belada et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive value of Fc gamma receptor IIIa genotype in response to conatumumab in three phase II studies.
- (2017) Y. Pan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis.
- (2017) W. Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Evaluation of M30 and M65 ELISA Cell Death Assays as Circulating Biomarkers in a Drug-Sensitive Tumor, Testicular Cancer
- (2015) Esther C. de Haas et al. NEOPLASIA
- A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma
- (2014) Chuanying Geng et al. AMERICAN JOURNAL OF HEMATOLOGY
- A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer†
- (2013) A. L. Cohn et al. ANNALS OF ONCOLOGY
- Death receptors as targets in cancer
- (2013) O Micheau et al. BRITISH JOURNAL OF PHARMACOLOGY
- A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
- (2013) Zev A. Wainberg et al. Clinical Colorectal Cancer
- A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2013) Luis Paz-Ares et al. Journal of Thoracic Oncology
- A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer
- (2013) Martin Reck et al. LUNG CANCER
- Structural determinants of DISC function: New insights into death receptor-mediated apoptosis signalling
- (2013) Tamas Sessler et al. PHARMACOLOGY & THERAPEUTICS
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
- (2013) J. E. Allen et al. Science Translational Medicine
- Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis
- (2013) L Steinhart et al. Cell Death & Disease
- Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
- (2013) Andres Forero-Torres et al. Cancer Medicine
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- (2012) H. L. Kindler et al. ANNALS OF ONCOLOGY
- Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor Growth
- (2012) Nicholas S. Wilson et al. CANCER CELL
- An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation
- (2012) Bok-Soon Lee et al. CANCER LETTERS
- Translating TRAIL-receptor targeting agents to the clinic
- (2012) Martha W. den Hollander et al. CANCER LETTERS
- Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway
- (2012) Yeong-In Yang et al. CARCINOGENESIS
- First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study
- (2012) George D. Demetri et al. EUROPEAN JOURNAL OF CANCER
- A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres
- (2012) Hyemin Kim et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- XIAP Inhibition and Generation of Reactive Oxygen Species Enhances TRAIL Sensitivity in Inflammatory Breast Cancer Cells
- (2012) J. L. Allensworth et al. MOLECULAR CANCER THERAPEUTICS
- Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
- (2012) J. E. Allen et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
- (2012) V. Subbiah et al. MOLECULAR CANCER THERAPEUTICS
- Small-molecule activation of the TRAIL receptor DR5 in human cancer cells
- (2012) Gelin Wang et al. Nature Chemical Biology
- Akt, FoxO and regulation of apoptosis
- (2011) Xinbo Zhang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery
- (2011) Francois Fay et al. BIOMATERIALS
- Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis
- (2011) E W Duiker et al. BRITISH JOURNAL OF CANCER
- Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer
- (2011) Jean-Nicolas Gallant et al. CANCER BIOLOGY & THERAPY
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis
- (2011) S. V. Garimella et al. MOLECULAR CANCER RESEARCH
- Off-Target Lapatinib Activity Sensitizes Colon Cancer Cells Through TRAIL Death Receptor Up-Regulation
- (2011) N. G. Dolloff et al. Science Translational Medicine
- Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy
- (2011) Ahmad R. Safa et al. Cancers
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2010) A Younes et al. BRITISH JOURNAL OF CANCER
- Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis
- (2010) John P. Plastaras et al. CANCER BIOLOGY & THERAPY
- Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737
- (2010) Geoffrey W. Krystal CANCER BIOLOGY & THERAPY
- Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab
- (2010) H. M. Stern et al. CLINICAL CANCER RESEARCH
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- (2010) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo
- (2010) G. Eisele et al. NEURO-ONCOLOGY
- Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1
- (2010) M Djavaheri-Mergny et al. ONCOGENE
- GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy
- (2010) N Heidari et al. Cell Death & Disease
- Tangeretin Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Downregulation of Phosphoinositide 3-Kinase/Akt Signaling Pathway
- (2009) E.-S. A. Arafa et al. CANCER RESEARCH
- Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model
- (2009) E. W. Duiker et al. CLINICAL CANCER RESEARCH
- Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
- (2009) C. H. Mom et al. CLINICAL CANCER RESEARCH
- XIAP discriminates between type I and type II FAS-induced apoptosis
- (2009) Philipp J. Jost et al. NATURE
- The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP
- (2009) M.D. Siegelin et al. NEUROCHEMISTRY INTERNATIONAL
- Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
- (2008) F. Anthony Greco et al. LUNG CANCER
- TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5
- (2008) Y. Zhang et al. MOLECULAR CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation